Actinium Pharmaceuticals, Inc.

AMEX:ATNM

Biotechnology

Healthcare
$1.64 +15.94%

+$0.22 today

Market cap
$51.56M
Beta
0.02
P/E (TTM)
4.4
EPS (TTM)
$0.36
52W Low $0.74High $1.74

Volume 0.18M

Average 0.15M

ATNM Income Before Tax

Profit after all operating and non-operating items but before income tax.

Actinium Pharmaceuticals, Inc.AMEX: ATNM

Income Before Tax · Q2 FY2026 · quarter ended Jun 2026

Income before tax turns positive

Q2 FY2026 income before tax was $27.9M, compared with -$6.88M a year earlier. Trailing-twelve-month income before tax was $11.31M.

Context

  • Income before tax amounted to 37652.2% of revenue in FY2025.
  • Income before tax grew in size in 1 of the last 3 fiscal years.

What to watch

Whether quarterly income before tax holds near $27.9M or moves back toward the trailing-twelve-month quarterly average of $2.83M.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterJun 2026
$27.9M+605.3% QoQ
Last fiscal yearDec 2025
-$33.89M+11.4% YoY
LTMJun 2026
$11.31M+127.6% YoY
Income Before Tax past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+505.7%——
1 year+11.4%——
3-year CAGR———
5-year CAGR——
10-year CAGR——

Income Before Tax history

USD · from the income statement

Latest · FY2025
(33.89M) USD
Year-over-year change
+11.4%

Income Before Tax vs competitors

How ATNM compares with its peers on the latest reported figures

  • ATNM's LTM Jun 2026 income before tax of $11.31M is the highest of the 5 companies compared; the peer median is -$37.14M.
  • Its year-over-year change of +127.6% is the highest of 5, against a peer median of +13.0%.
  • Income before tax amounts to 32.2% of revenue for ATNM, versus a peer median of 58.5%.
ATNM Competitors Peer median
Income Before Tax for ATNM and competitors
Company Period LTM YoY 3-year CAGR% of revenue
ATNMActinium Pharmaceuticals, Inc.LTM Jun 2026$11.31M +127.6%—32.2%
XLOXilio Therapeutics, Inc.LTM Mar 2026-$31.3M +42.4%—58.5%
PDSBPDS Biotechnology CorporationLTM Mar 2026-$33.36M +11.1%——
ANVSAnnovis Bio, Inc.LTM Mar 2026-$40.92M -40.8%——
OKUROnKure Therapeutics, Inc.LTM Mar 2026-$58.75M +14.8%——
Peer median (excluding ATNM) -$37.14M+13.0%—58.5%

Competitors are the stored peer set for ATNM. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue1.14M1.03M81K090K
Cost of Revenue524K00811K0
Gross Profit620K1.03M81K(811K)90K
Gross Margin54.2%100.0%100.0%—100.0%
Research & Development17.51M23.14M38.67M30.05M21.12M
Selling, General & Admin8.08M12M13.33M12.08M15.21M
Operating Expenses25.58M35.13M52M41.31M36.34M
Depreciation & Amortization524K699K790K811K821K
EBITDA(24.25M)(32.32M)(48.03M)(37.43M)(33.07M)
EBITDA Margin-2119.8%-3137.7%-59293.8%—-36740.0%
Operating Income(24.96M)(34.1M)(51.92M)(42.12M)(36.25M)
Operating Margin-2182.2%-3311.1%-64098.8%—-40274.4%
Interest Income190K1.09M3.1M3.88M2.36M
Interest Expense00000
Other Income / Expenses190K1.09M3.1M3.88M2.36M
Income Before Tax(24.77M)(33.02M)(48.82M)(38.24M)(33.89M)
Pre-Tax Margin-2165.6%-3205.5%-60269.1%—-37652.2%
Income Tax Expense00000
Net Income(24.77M)(33.02M)(48.82M)(38.24M)(33.89M)
Net Margin-2165.6%-3205.5%-60269.1%—-37652.2%
EPS (Basic)(1.20)(1.37)(1.83)(1.27)(1.09)
EPS (Diluted)(1.20)(1.37)(1.83)(1.27)(1.09)
Weighted Avg Shares20.57M24.14M26.6M30.07M31.2M
Weighted Avg Shares (Diluted)20.57M24.14M26.6M30.07M31.2M

Actinium Pharmaceuticals, Inc.

AMEX:ATNM

Intrinsic Alpha fair value

Locked

Current Price

$1.64

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.